Search Result

Results for "

RNA aptamer-based

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Bcl-2 Family (1) Early 2 Factor (E2F) (1) Factor Xa (2) Ligands for Target Protein for PROTAC (1) NF-κB (1) PDGFR (1) PROTACs (1) Target Protein Ligand-Linker Conjugates (1) VEGFR (1)
By Research Areas:	Cancer (4)
Oligonucleotides:	Aptamers (3)

Inhibitors & Agonists

Oligonucleotides

Targets Recommended: MicroRNA mRNA RNA MTase Small Interfering RNA (siRNA) DNA/RNA Synthesis Aminoacyl-tRNA Synthetase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-175397

Dth DFHBI-thalidomide	PROTACs NF-κB Early 2 Factor (E2F) Bcl-2 Family VEGFR	Cancer
Dth (DFHBI-thalidomide) is an RNA aptamer-based PROTAC degrader. Dth can degrade a variety of endogenous proteins (such as mCherry, p50, p65 and E2F1) by replacing the 3′ module on the RNA scaffold with the RNA aptamer corresponding to the target protein. Dth upregulates IκB-α and Bax, and downregulates Bcl-2 and VEGF. Dth generates green fluorescence upon binding to the Broccoli RNA aptamer, enabling the tracing of RNA scaffolds. Dth can be used in cancer-related research .

HY-160053

*Gint4.T aptamer* sodium**	PDGFR	Cancer
Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment .

HY-153835

Pegnivacogin	Factor Xa	Others
Pegnivacogin is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen.

HY-176801

Oxide-DFHBI-demethyl	Ligands for Target Protein for PROTAC	Cancer
Oxide-DFHBI-demethyl is a target aptamer ligand (Ligand for Target Protein for PROTAC). Oxide-DFHBI-demethyl can be used for synthesis of RNA aptamer-based PROTAC Dth (HY-175397) .

HY-176802

Oxide-DFHBI-demethyl-C6-NH2	Target Protein Ligand-Linker Conjugates	Cancer
Oxide-DFHBI-demethyl-C6-NH2 is a Target Protein Ligand-Linker Conjugate that incorporates a target aptamer ligand (HY-176801) and a PROTAC linker (HY-79577), which recruits E3 ligases. Oxide-DFHBI-demethyl-C6-NH2 can be used for synthesis of RNA aptamer-based PROTAC Dth (HY-175397) .

HY-153835A

Pegnivacogin sodium	Factor Xa	Others
Pegnivacogin sodium is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen.

Cat. No.	Product Name		Classification

HY-160053

*Gint4.T aptamer* sodium**		Aptamers
Gint4.T aptamer sodium is a nuclease-resistant RNA aptamer-based antagonist targeting platelet-derived growth factor receptor beta (PDGFRβ) (Kd: 9.6 nM). Gint4.T aptamer sodium inhibits PDGFRβ heterodimerization and EGFR transactivation. It can significantly inhibit cell migration and proliferation, induce differentiation and prevent tumor growth in vivo. Gint4.T aptamer sodium specifically inhibits PDGFRβ-mediated tropism of mesenchymal stem cells (MSCs) toward the tumor microenvironment .

HY-153835

Pegnivacogin		Aptamers
Pegnivacogin is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen.

HY-153835A

Pegnivacogin sodium		Aptamers
Pegnivacogin sodium is a novel RNA-aptamer based factor IXa inhibitor featuring a reversal agent, anivamersen.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.